Travere Therapeutics reported that Chief Executive Officer Eric M. Dube completed the sale of a combined 60,000 shares of company common stock on January 23 and January 27, 2026. The disposals were carried out pursuant to a pre-established 10b5-1 trading plan and produced aggregate proceeds of approximately $1.8 million.
The transactions were executed at weighted average prices of $30.0127 and $30.097, respectively. On January 23, the shares transacted in a price band between $30.00 and $30.13. On January 27, the trading range for the sales was between $30.00 and $30.49.
Concurrent with these sales, Dube exercised stock options to acquire 60,000 shares of Travere common stock at an exercise price of $15.46 per share. The total cash value associated with exercising those options was $927,600.
In separate regulatory news cited by the company, the U.S. Food and Drug Administration has extended the review timeline for Travere's supplemental New Drug Application for Filspari, a therapy for focal segmental glomerulosclerosis, or FSGS. The new target action date under the Prescription Drug User Fee Act is now set for April 13, 2026.
The extension follows Travere's submission of additional information the FDA had requested to better characterize the clinical benefit of Filspari. The agency has classified the company's responses as a Major Amendment to the application.
Analyst commentary noted in the company update includes Stifel's decision to maintain a Hold rating on Travere with a price target of $31.00. Stifel referenced the FDA's request for further data on the clinical benefits of Sparsentan, another Travere treatment for FSGS.
The company statement and analyst notes emphasize that the FDA's requests and the resulting extension have introduced regulatory uncertainty. Market participants have reacted in varying ways, and Travere's share price has reflected that mixed response as the company moves through these regulatory milestones.
These developments combine an insider's option exercise and subsequent sale executed under a predetermined plan with an ongoing regulatory review process that now carries a revised PDUFA date. The outcomes of the FDA's review and any further communications will determine the next regulatory steps for Travere and the clinical programs referenced.